36:
108:
195:
which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on
Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
236:(C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.
573:
69:
558:
563:
454:
340:
568:
548:
543:
419:
232:
A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targets
55:
322:
87:
273:
344:
420:"Noxxon Presents Top-Line Data from Nox-A12 Monotherapy Part of Ongoing Metastatic Colorectal and Pancreatic Cancer Trial"
233:
65:
286:
Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects".
200:
51:
46:
455:"Noxxon's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference"
370:
for "Olaptesed (NOX-A12) Alone and in
Combination With Pembrolizumab in Colorectal and Pancreatic Cancer" at
553:
491:"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys"
406:
for "NOX-A12 in
Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia" at
240:
477:
442:
407:
389:
371:
118:
388:
for "NOX-A12 in
Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma" at
520:
318:
295:
239:
A different
Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressive
510:
502:
254:
A third
Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment of
243:. Favorable results were reported in June 2014 in a company press release. NOX-E36 targets
192:
515:
490:
537:
476:
for "Efficacy of NOX-H94 on Anemia of
Chronic Disease in Patients With Cancer" at
472:
437:
402:
384:
366:
506:
35:
107:
17:
524:
441:
for "NOX-E36 in
Patients With Type 2 Diabetes Mellitus and Albuminuria" at
313:
Eulberg D; et al. (2006), "Spiegelmers for
Therapeutic Applications",
299:
206:, which are of mirror-image configuration compared to naturally occurring
218:
191:, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in
140:
255:
136:
210:-RNA molecules. The company calls these agents Spiegelmers, from
248:
244:
29:
180:
61:
229:
Some
Spiegelmer candidates were in clinical trials.
199:
TME Pharma develops drugs using technology yielding
157:
Maurizio PetitBon, Chairman of the supervisory board
176:
163:
146:
132:
124:
114:
341:"News Review: Aram Mangasarian, Noxxon Pharma AG"
574:Medical and health organisations based in Berlin
50:, potentially preventing the article from being
8:
559:Pharmaceutical companies established in 1997
100:
564:Biotechnology companies established in 1997
217:The L-RNA are resistant to the natural RNA
106:
99:
70:reliable, independent, third-party sources
514:
425:(Press release). Noxxon. October 2, 2018.
317:(in German), WILEY-VCH, pp. 417–42,
88:Learn how and when to remove this message
335:
333:
64:by replacing them with more appropriate
489:Schwoebel F, et al. (March 2013).
266:
47:too closely associated with the subject
460:(Press release). Noxxon. June 2, 2014.
343:. pharmatelevision.com. Archived from
276:. Noxxon.com. Retrieved on 2018-02-14.
7:
569:German companies established in 1997
549:Pharmaceutical companies of Germany
544:Biotechnology companies of Germany
25:
214:, the German word for "mirror."
45:may rely excessively on sources
34:
1:
507:10.1182/blood-2012-09-456756
27:German biotechnology company
590:
288:Curr Opin Drug Discov Dev
105:
470:Clinical trial number
435:Clinical trial number
400:Clinical trial number
382:Clinical trial number
364:Clinical trial number
154:Aram Mangasarian, CEO
315:The Aptamer Handbook
258:of chronic disease.
241:diabetic nephropathy
165:Number of employees
102:
478:ClinicalTrials.gov
443:ClinicalTrials.gov
408:ClinicalTrials.gov
390:ClinicalTrials.gov
372:ClinicalTrials.gov
119:Aktiengesellschaft
209:
203:
186:
185:
181:www.tmepharma.com
172:
98:
97:
90:
16:(Redirected from
581:
529:
528:
518:
486:
480:
468:
462:
461:
459:
451:
445:
433:
427:
426:
424:
416:
410:
398:
392:
380:
374:
362:
356:
355:
353:
352:
337:
328:
327:
310:
304:
303:
283:
277:
271:
207:
201:
170:
110:
103:
93:
86:
82:
79:
73:
38:
30:
21:
589:
588:
584:
583:
582:
580:
579:
578:
534:
533:
532:
488:
487:
483:
469:
465:
457:
453:
452:
448:
434:
430:
422:
418:
417:
413:
399:
395:
381:
377:
363:
359:
350:
348:
339:
338:
331:
325:
312:
311:
307:
285:
284:
280:
272:
268:
264:
227:
193:Berlin, Germany
166:
149:
94:
83:
77:
74:
59:
39:
28:
23:
22:
15:
12:
11:
5:
587:
585:
577:
576:
571:
566:
561:
556:
551:
546:
536:
535:
531:
530:
501:(12): 2311–5.
481:
463:
446:
428:
411:
393:
375:
357:
329:
323:
305:
278:
265:
263:
260:
247:, also called
226:
223:
204:-RNA molecules
184:
183:
178:
174:
173:
167:
164:
161:
160:
159:
158:
155:
150:
147:
144:
143:
134:
130:
129:
126:
122:
121:
116:
112:
111:
96:
95:
42:
40:
33:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
586:
575:
572:
570:
567:
565:
562:
560:
557:
555:
554:German brands
552:
550:
547:
545:
542:
541:
539:
526:
522:
517:
512:
508:
504:
500:
496:
492:
485:
482:
479:
475:
474:
467:
464:
456:
450:
447:
444:
440:
439:
432:
429:
421:
415:
412:
409:
405:
404:
397:
394:
391:
387:
386:
379:
376:
373:
369:
368:
361:
358:
347:on 2013-05-24
346:
342:
336:
334:
330:
326:
324:3-527-31059-2
320:
316:
309:
306:
301:
297:
294:(2): 253–61.
293:
289:
282:
279:
275:
270:
267:
261:
259:
257:
252:
250:
246:
242:
237:
235:
230:
224:
222:
220:
215:
213:
205:
197:
194:
190:
182:
179:
175:
168:
162:
156:
153:
152:
151:
145:
142:
138:
135:
131:
127:
123:
120:
117:
113:
109:
104:
92:
89:
81:
78:December 2018
71:
67:
63:
57:
53:
49:
48:
43:This article
41:
37:
32:
31:
19:
18:Noxxon Pharma
498:
494:
484:
471:
466:
449:
436:
431:
414:
401:
396:
383:
378:
365:
360:
349:. Retrieved
345:the original
314:
308:
291:
287:
281:
269:
253:
238:
231:
228:
216:
211:
198:
188:
187:
133:Headquarters
115:Company type
84:
75:
60:Please help
44:
473:NCT01691040
438:NCT01547897
403:NCT01486797
385:NCT01521533
367:NCT03168139
538:Categories
351:2013-07-16
262:References
189:TME Pharma
148:Key people
101:TME Pharma
62:improve it
52:verifiable
274:Investors
221:enzymes.
66:citations
525:23349391
300:12669461
225:Products
219:nuclease
516:3606066
212:Spiegel
177:Website
141:Germany
125:Founded
56:neutral
523:
513:
321:
298:
256:anemia
234:CXCL12
171:(2017)
137:Berlin
495:Blood
458:(PDF)
423:(PDF)
245:MCP-1
521:PMID
319:ISBN
296:PMID
249:CCL2
128:1997
54:and
511:PMC
503:doi
499:121
251:.
169:10
68:to
540::
519:.
509:.
497:.
493:.
332:^
290:.
139:,
527:.
505::
354:.
302:.
292:6
208:D
202:L
91:)
85:(
80:)
76:(
72:.
58:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
